SC seeks details on cost, availability of NAT in hospital to prevent transfusion related infection

The Supreme Court of India has called for comprehensive information regarding the cost and availability of Nucleic Acid Testing (NAT) in hospitals as a measure to prevent transfusion-related infections. This directive arises from ongoing concerns about the safety of blood transfusions, particularly in light of rising cases of transfusion-transmitted infections. The court is particularly interested in understanding how accessible NAT is in various healthcare facilities across the country, as well as its associated costs, to ensure that blood transfusions are conducted safely and effectively. The Supreme Court's inquiry underscores the importance of implementing advanced testing methods to safeguard patients' health, especially in a country with a high demand for blood transfusions. This move is expected to drive improvements in blood safety protocols and promote greater accountability among healthcare providers. The decision reflects a growing recognition of the need for stringent measures to enhance patient safety and reduce the risk of infections from blood products in India.